Expression of α6 integrin, a laminin receptor, on tumor cell surfaces is associated with reduced patient survival and increased metastasis in a variety of tumors. In prostate cancer, tumor extracapsular escape occurs in part via laminin-coated nerves and vascular dissemination, resulting in clinically significant bone metastases. We previously identified a novel form of α6 integrin, called α6p, generated by urokinase-type plasminogen activator-dependent cleavage of the laminin-binding domain from the tumor cell surface. Cleavage increased laminin-dependent migration. Currently, we used the known conformation sensitivity of integrin function to determine if engagement of the extracellular domain inhibited integrin cleavage and the extravasation step of metastasis. We show that α6 integrin was present on prostate carcinoma escaping the gland via nerves. Both endogenous and inducible levels of α6p were inhibited by engaging the extracellular domain of α6 with monoclonal antibody J8H. J8H inhibited tumor cell invasion through Matrigel. A severe combined immunodeficient mouse model of extravasation and bone metastasis produced detectable, progressive osteolytic lesions within 3 weeks of intracardiac injections. Injection of tumor cells, pretreated with J8H, delayed the appearance of metastases. Validation of the α6 cleavage effect on extravasation was confirmed through a genetic approach using tumor cells transfected with uncleavable α6 integrin. Uncleavable α6 integrin significantly delayed the onset and progression of osseous metastases out to six weeks post-injection. The results suggest that α6 integrin cleavage permits extravasation of human prostate cancer cells from circulation to bone and can be manipulated to prevent metastasis. [Cancer Res 2009;69(12):5007–14]
The α6 integrin, a laminin receptor, is expressed on tumor cell surfaces and is associated with poor patient prognosis, reduced survival, and increased metastasis in a variety of tumors ( 1– 4). Integrins are type I transmembrane heterodimers composed of α and β subunits. The heterodimer confers ligand-binding specificity to a particular extracellular matrix substrate ( 5). Integrins α6β1 or α6β4 are receptors for laminin 111 (laminin 1), laminin 511 (laminin 10), or laminin 332 (laminin 5), respectively. In human prostate cancer, escape from the gland occurs in part via laminin 511-coated nerves ( 6, 7) followed by dissemination and subsequent escape from circulation, resulting in clinically significant bone metastasis ( 8, 9). Additionally, mouse and human bone marrow have both been shown to be rich laminin environments ( 10– 12).
The two most persistently expressed integrin heterodimer pairs in human prostate cancer are the laminin-binding α6β1 and α3β1 receptors ( 13– 15). In addition, the basement membrane component laminin 332 is not expressed, whereas laminin 511 persists, creating an environment selective for α6β1 function ( 16). We previously reported a novel form of α6 integrin, called α6p, generated by cleavage of the laminin-binding domain from the tumor cell surface by urokinase-type plasminogen activator (uPA), a prometastatic factor ( 17, 18). Expression levels of both uPA and its cognate receptor were shown to be negatively correlated with prostate cancer patient survival ( 19, 20). The uPA-dependent cleavage of α6 integrin increased cellular migration in vitro and was proposed as a mechanism for tumor cell release from adhesion to laminin ( 21). We initiated the current study to determine whether inhibiting cleavage of the α6β1 integrin would alter the ability of tumor cells to reach the bone from the circulation.
Integrins provide linkage from the extracellular environment to intracellular cytoskeletal components that focally interact at the internal portion of the receptor. This integrated function is necessary for cellular adhesion, migration, survival, and differentiation ( 13). Integrin function is dictated in part by changes in receptor conformation that results in the alteration of ligand affinity and “outside-in” signaling ( 22, 23). This was initially inferred by the generation of monoclonal antibodies that could bind extracellular domains and alter integrin conformation and activity. Experimentally, integrins can be activated or functionally blocked from adhesion by externally applied antibodies ( 24). Circulating levels of immunoglobulins that engage and block adhesion function of the α6β1 heterodimer, in patients with oral pemphigoid, results in formation of blisters and erosive lesions in the oral mucosa ( 25, 26).
We reasoned that engagement of extracellular epitopes on the receptor with α6 integrin antibodies would block uPA-mediated cleavage. We report here the activity of the previously characterized J8H antibody that does not affect cellular adhesion on laminin ( 27) but does block integrin cleavage. J8H was used to test the influence of blocking integrin cleavage on the appearance of bone metastasis. A separate genetic approach, tumor cells expressing an uncleavable α6 integrin mutant ( 21, 28), was used as an independent technique to determine if extravasation required integrin cleavage.
Materials and Methods
Antibodies and reagents. J8H, a mouse monoclonal antibody, recognizes an extracellular epitope of α6 integrin and was a generous gift from Dr. A. Sonnenberg ( 27). The integrin α6 rat monoclonal antibody J1B5 was generated by Dr. Caroline H. Damsky ( 29). AA6NT, a rabbit polyclonal antibody, was generated against a recombinant fragment of the NH2-terminal integrin α6 β-barrel domain and was used for immunohistochemistry analysis of archival material. In contrast, AA6A is a rabbit polyclonal antibody, recognizing the intracellular COOH-terminal domain of α6 integrin, previously characterized by us and used for Western blot analysis ( 21). Donkey anti-mouse Alexa 488-conjugated antibodies and anti-rabbit horseradish peroxidase antibodies were obtained from Invitrogen. Human, single-chain, activated, urokinase was obtained from Millipore. Growth factor-reduced Matrigel was from BD Biosciences.
Cell culture. Cells were maintained in Iscove's modified Dulbecco's medium (IMDM; Life Technologies) supplemented with 10% heat-inactivated fetal bovine serum (Hyclone Laboratories) and 1% penicillin/streptomycin (Invitrogen) at 37°C in a 5% CO2 atmosphere at constant humidity. PC3 and DU145 cells were obtained from the American Type Culture Collection and PC3N cells were previously characterized by us ( 30). Cell line identities were verified using genomic probes reported by others ( 31). The PC3B1 cells were isolated from the bone marrow of severe combined immunodeficient (SCID) mice that had been injected 6 weeks previously with the PC3 cell line. The bone marrow containing the tumor cells was retrieved with PBS and the PC3B1 cells were propagated in tissue culture. PC3B1 α6 wild-type (WT) and PC3B1 α6 RR cell lines were grown under blasticidin (Invitrogen) selection pressure (3 μg/mL). 293FT cells, used for generation of lentivirus, were grown in MEM supplemented with 10% fetal bovine serum and geneticin (500 μg/mL; Invitrogen). For antibody blocking experiments, cells were grown under optimal growth conditions for 24 h followed by replacement of medium with 5 mL complete IMDM containing J8H (20 μL/mL). J8H/medium replacement was done every 24 h.
Human prostate tissue immunohistochemistry. Prostate tissues were harvested, fixed in 10% neutral buffered formalin for 24 h, processed, and embedded in paraffin using the Tissue Acquisition and Cellular/Molecular Analysis Shared Service of The Arizona Cancer Center. Immunohistochemistry was done using the affinity-purified AA6NT rabbit polyclonal antibody diluted to 1:700 and stained on a Discovery XT Automated Immunostainer (Ventana Medical Systems). Antigen retrieval was done using a borate-EDTA at 100°C.
uPA-mediated cleavage of α6 integrin. In immunoprecipitation experiments ( 21), α6 integrin was retrieved from PC3N lysate using antibodies J1B5 or J8H for 3 h at 4°C and the resulting Sepharose G beads were resuspended in 500 μL Dulbecco's PBS (Invitrogen) with 20 ng activated single-chain uPA. The mixture was incubated overnight at 4°C with rotation, centrifuged, resuspended in nonreducing gel sample buffer, and analyzed by SDS-PAGE. In cell surface experiments, PC3N cells were harvested with PBS containing 5 mmol/L EDTA and resuspended in 500 μL serum-free IMDM. Cells were incubated for 30 min with or without J8H antibody at 4°C. Activated uPA (25 μg) was added to the cells and incubated for 3 h at 37°C. Cells (5 × 106) were washed once in PBS and lysed in radioimmunoprecipitation assay buffer (50 mmol/L Tris, 150 nmol/L NaCl, 1% Triton, 0.10% SDS, 1% deoxycholate, 1 mmol/L phenylmethylsulfonyl fluoride, 1 mmol/L leupeptin, and 1 mmol/L aprotinin). Following immunoprecipitation, samples were analyzed by SDS-PAGE.
Flow cytometry. Cells were harvested using PBS containing 5 mmol/L EDTA, washed in PBS, and resuspended in 200 μL PBS with 0.02% bovine serum albumin with J8H hybridoma supernatant (1:20). All antibody incubations were carried out on ice for 30 min. Antibody binding was detected by Alexa 488 anti-mouse secondary antibody (1:1,000) and analyzed using the Flow Cytometry Service of The Arizona Cancer Center.
Invasion assay. Growth factor-reduced Matrigel (50 μL) diluted (1:3) with serum-free IMDM was placed in 8.0 μm cell culture inserts (BD Falcon) and allowed to solidify for 1 h at 37°C. Inserts were placed into a 24-well plate. PC3B1 cells (1 × 105) were placed in the top insert chamber with 200 μL serum-free IMDM. IMDM (600 μL) supplemented with 10% fetal bovine serum was pipetted into the bottom well below the insert. After a 20 h incubation, inserts were washed in PBS and Matrigel was removed with a cotton swab. Cells on the underside of the insert were fixed/permeabilized in methanol/acetone and stained with 4′,6-diamidino-2-phenylindole (1 μg/mL) for nuclei detection. Cell numbers were counted using a Zeiss Axiophot inverted microscope. Three images were collected per insert and experiments were done in triplicate.
SCID mouse model of extravasation. Mice experiments were conducted with animal care and use committee approval and done using the facilities and staff of the Experimental Mouse Shared Service at The Arizona Cancer Center. Left ventricle injections of single-cell suspensions of ∼0.5 million cells in 0.2 mL PBS were done with a 27-gauge needle as described previously ( 32, 33). Mice were anesthetized with isoflurane (2-3% delivered through a nose cone). Twelve mice were used in each treatment group as dictated by statistical power analysis software. 5 One-way ANOVA between two treatment groups was used as the model with a 80% chance of detecting a difference and no more than a 5% chance of error. Mice receiving incorrectly placed injections or containing chest tumors at necropsy were removed from the study. Animals were terminated by CO2 inhalation if microfractures were detected by radiographic images or if they showed signs of pain/suffering as specified by protocol.
Radiographic imaging. Animals were anesthetized with intraperitoneal injections of ketamine/HCl (50 mg/kg) and xylazine (15-20 mg/kg). Digital radiographs were collected on live animals 4, 5, and 6 weeks after tumor cell injection using a Faxitron MX-20 machine at 7 μm nominal resolution with a X-ray current of 300 μA and a voltage of 26 kV (Faxitron X-ray). Each digital image required 10 s. Animals were allowed to recover from anesthesia and returned to the animal care facility. Images were read and interpreted by G.D.P. (board-certified radiologist) without knowledge of the treatment groups.
Generation of PC3B1 integrin α6 RR and WT mutant cell lines. The α6 integrin cDNA was amplified with primers (5′-CACCCGACTCACTATAGGGAGACCCAAGC and 3′-CTATGCATCAGAAGTAAGCCTCTCTTTATCAGATG) and directionally cloned into the pENTR/D-TOPO vector (Invitrogen). The QuikChange II XL site-directed mutagenesis kit (Stratagene) was used to introduce alanine mutations at arginine residues 594 and 595 (RR), with primers previously characterized ( 21). Using the Gateway recombination cloning method (ref. 34; Invitrogen), α6 integrin WT and RR mutant pENTR/D-TOPO vectors were recombined into the pLenti/UbC/V5-DEST expression vector. Generation of replication-incompetent lentiviral stocks was done by transfecting the pLenti/UbC/α6 integrin vector in combination with ViraPower Packing Mix and Lipofectamine 2000 (Invitrogen) into 293FT cells. Virus was harvested after 72 h, centrifuged at high speed for 20 min at 4°C, and frozen at −80°C. Lentivirus was used to infect PC3B1 cells. Three days following transfection, cells were placed under blasticidin (3 μg/mL) selection. Expression of UbC-driven α6 integrin RR mutant expression was confirmed by reverse transcription-PCR as described previously ( 28).
Expression of α6 integrin on tumor cell surface during escape from human prostate gland. Previous work has shown α6 integrin expression in human normal prostate, prostatic intraepithelial neoplasia (PIN), and invasive cancer using frozen tissues and indirect immunofluorescence microscopy. Here, using an alternative method with human formalin-fixed, paraffin-embedded archival prostate tissue, we show simultaneous detection of tumor cell antigens and cell types (fibroblast, Schwann, and endothelial) or structures (nerves and vessels). Detection of α6 integrin using formalin-fixed, paraffin-embedded tissues confirmed that normal prostate epithelial cells display polarized expression of α6 integrin at the basal cell/stromal interface ( Fig. 1A, Normal ) as shown previously by us and others ( 14).
We observed loss of α6 integrin polarity during progression from PIN ( Fig. 1A, PIN) to invasive cancer ( Fig. 1A, Cancer). α6 Integrin was expressed by vessels ( Fig. 1A, PIN, arrowhead) as reported previously. We also show a new finding that α6 integrin was expressed on the tumor cell surface during neural invasion ( Fig. 1A, NI). Neural invasion by the tumor includes invasion both around and within the nerve. Perineural and endoneural invasion is characteristic of tumor present in the peripheral zone of the prostate gland ( 6, 35). The presence of α6 integrin on perineural fibroblasts and Schwann cells of the nerve were observed, consistent with previous reports ( 36– 38). Both antibodies (AA6A and AA6NT) used in this study recognize the full-length α6 integrin by Western blot ( Fig. 1B). The AA6A antibody was generated against the COOH-terminal cytoplasmic domain of the α6 integrin and thus will recognize the cleaved integrin receptor α6p under nonreduced conditions (NR). Under reducing conditions (R), AA6A recognizes the α6 light chain that is shifted to ∼25 kDa. In contrast, the AA6NT antibody, raised against the NH2-terminal domain of the α6 integrin, recognizes the NH2-terminal fragment, called α6N. The α6N heavy chain shifts to an apparent larger MW on reduction (R), as expected. A schematic illustrating the relative location of the epitopes on integrin α6 recognized by the four antibodies (AA6NT, J8H, J1B5, and AA6A) used in this study and the uPA cleavage site (RR) is shown ( Fig. 1C).
SCID mouse model of prostate cancer extravasation. Injection of human tumor cells into the left ventricle of the mouse heart ensured broad dissemination of tumor cells via the circulation. The model is relevant to human prostate cancer progression because metastases develop from the arterial distribution of tumor emboli in circulation ( 39). We developed a model for generating reproducible and aggressive bone metastases by comparing the effectiveness of PC3 cells versus PC3B1 cells ( Fig. 2A ). Human tumor within the bone expressed α6 integrin on the cell surface ( Fig. 2B). Radiograph images of the entire skeleton were surveyed on all animals and a metastasis in any bone resulted in a positive score. All bone metastases detected were lytic lesions located primarily within the metaphysis and abutting the epiphyseal plate ( Fig. 2C, arrows), and all were progressive (data not shown). This model system enabled testing of how tumor cell properties influence extravasation and development of bone metastases.
α6 integrin antibody J8H inhibited uPA-mediated cleavage of α6 integrin. Prostate cancer cell lines PC3, PC3N, DU145, and PC3B1 produced varying amounts of α6p under normal growth conditions ( Fig. 3A ). The PC3N cell line was chosen for further study because α6 integrin expressed on the cell surface was primarily in the full-length form. α6 Integrin was retrieved via immunoprecipitation using either J1B5 or J8H antibody and its ability to be cleaved was tested by addition of uPA. α6 integrin retrieved by J1B5 was converted to α6p integrin in the presence of uPA as shown by the decrease in the full-length form (α6) and a corresponding increase in α6p form ( Fig. 3B). In contrast, α6 integrin retrieved by J8H remained in the full-length form (α6) in the presence of uPA ( Fig. 3B).
We next tested if J8H antibody blocked integrin cleavage on the cell surface. PC3N cells were pretreated with or without J8H before incubation with uPA. In the absence of J8H and uPA or the absence of uPA alone, the α6 integrin remained in the full-length form on the cells ( Fig. 3C). The addition of uPA without the J8H antibody resulted in α6 integrin converted to α6p as shown by the decrease in the full-length form (α6) and a corresponding increase in the cleavage product, α6p ( Fig. 3C). Importantly, pretreatment of cells with J8H antibody prevented the production of the cleaved form (α6p) via uPA ( Fig. 3C). These results indicated that induction of α6p by the exogenous addition of uPA can be blocked by either engaging the α6 integrin in an immunoprecipitation reaction or engaging α6 integrin on the cell surface with the antibody, J8H.
We next tested if J8H could block the production of α6p in DU145 cells. DU145 cells were selected for this experiment because they do not require exogenous addition of uPA to generate α6p integrin ( Fig. 3A). Previously published data indicated that the biological half-life of α6p on the cell surface was ∼72 h ( 40). Therefore, experiments were designed to test the ability of J8H to block endogenous α6p production over several days. J8H treatment of DU145 cells for 48 h dramatically decreased the endogenous production of α6p ( Fig. 3D). Inhibition of α6p production was also observed after 96 h.
J8H diminished the invasive potential of PC3B1 cells. The data thus far indicated that J8H prevented α6p production. Previous work suggested that preventing α6p production would decrease cell migration on laminin ( 21, 28). Because tumor invasion of laminin-coated nerves was observed ( Fig. 1A), we next determined whether J8H altered cancer cell invasion on laminin. We used a Matrigel invasion assay in the presence of purified laminin 111, a ligand of α6 integrin. PC3B1 cells were selected for this experiment due to their aggressive nature in the mouse metastasis model and because they produce α6p ( Fig. 2A). We first confirmed, through flow cytometry, that PC3B1 cells have surface expressed α6 integrin recognized by the J8H antibody ( Fig. 4A ). Cells were applied to Matrigel-coated inserts in the presence of J8H to determine if invasion was altered. After 20 h of incubation, the ability of PC3B1 cells to invade (control) was inhibited significantly in the presence of J8H antibody ( Fig. 4B). The image results were quantitated and ∼80% of the cells were inhibited from reaching the underside of the Matrigel-coated insert in the presence of J8H ( Fig. 4C).
Pretreatment of PC3B1 cells with J8H significantly delayed bone metastasis. Using the SCID mouse model of extravasation, we tested whether engagement of the α6 integrin with J8H, the cleavage blocking antibody, would inhibit bone metastasis. Previous work by others showed that tumor cells within the circulation can extravasate to bone within 1 to 2 h of injection ( 41– 43). Titration analysis of the J8H antibody was done by flow cytometry on PC3B1 cells to determine maximal surface labeling (data not shown). PC3B1 cells alone or J8H-treated cells were introduced into the circulation of SCID mice. The percentage of mice containing bone metastases was determined by digital radiographs of live animals 3, 4, 5, and 6 weeks later ( Fig. 5A ). Injection of PC3B1 cells resulted in ∼40% of the animals containing bone metastases within 3 weeks, and by 4 weeks, 80% of the animals contained bone metastasis ( Fig. 5A). By week 5, 80% of the animals required termination ( Table 1 ). In contrast, injection of PC3B1 cells pretreated with J8H resulted in no metastases within 3 weeks, and at 4 weeks, 80% of the animals were free of bone metastasis ( Fig. 5A). Interestingly, by week 5, 80% of the animals displayed bone metastases. By week 6, 80% of the animals required termination ( Table 1). The lesions detected in both groups of animals were osteolytic and progressive and arose primarily within the distal femur or proximal tibia ( Table 1). Of particular note, no lesions were detected in the vertebral column, the pelvic girdle, mandible, or skull (data not shown).
Mutation of α6 integrin cleavage site prevented PC3B1 bone metastasis. Our next step was to validate the J8H blocking results and determine if expression of an uncleavable α6 integrin in tumor cells would prevent extravasation to bone. We expressed the mutant form of α6 integrin, called RR, in PC3B1 cells. Endogenous levels of α6 integrin were not altered in this experiment. We have shown previously that cellular expression of the integrin RR mutant results in a fully functional receptor expressed on the cell surface, laminin-dependent adhesion, and viable tumor xenografts in a mouse model ( 21, 28). PC3B1 cells were transfected with either WT α6 integrin (PC3B1-WT) or α6 integrin containing alanine substitutions for arginine at amino acid positions 594 and 595 (PC3B1-RR). The expression level of the α6 integrin on the cell surface was comparable between the groups as determined by fluorescence-activated cell sorting analysis (data not shown). Injection of PC3B1-WT cells resulted in detectable bone metastasis in ∼10% of the animals within 3 weeks and 80% of the animals by weeks 4, 5, and 6 ( Fig. 5B, WT). In contrast, injection of the PC3B1-RR cells resulted in no lesions within 3 weeks, and only 10% of the animals showed lesions by weeks 4 and 5 ( Fig. 5B, RR). By week 6, less than half of the animals had detectable metastatic lesions ( Table 1). Radiographically, lesions that developed in the PC3B1-RR group were sharply circumscribed and not strikingly expansile compared with the PC3B1-WT. Of particular note, no lesions were detected in the vertebral column, the pelvic girdle, mandible, or skull (data not shown). Necropsy analysis detected no lesions in the lung, liver, or adrenal gland (data not shown).
In this study, we show that inhibiting α6 integrin cleavage on the tumor cell surface, either through antibody engagement or integrin mutation, will substantially delay the appearance of osseous metastases in a mouse xenograft model. The results reported here support the hypothesis that α6 integrin cleavage permits extravasation of tumor cells from the circulation because subcutaneous injection or direct injection of PC3N-RR mutant cells into bone has no affect on tumor growth at either location ( 28, 44). This is significant in the course of the human disease because extravasation from the circulation is a critical factor of metastatic spread ( 8, 39).
The influence of antibody engagement to delay the metastatic phenotype suggests that providing circulating levels of the integrin-specific antibody may be beneficial in preventing bone metastasis. The ability of J8H to reversibly delay the appearance of metastases by 1 week is significant because this corresponds to the expected half-life of therapeutic-type antibodies in the SCID mouse ( 45). Toxicity of J8H in the normal tissue is not expected because this antibody does not block cell adhesion to laminin ( 27). Previous work has shown that inhibiting the α6 adhesion function will block experimental metastasis to the lung ( 14). However, the utility of this approach as a therapeutic strategy appears limited. Circulating levels of immunoglobulin specific for blocking α6 integrin adhesion function in humans result in the formation of blisters and erosive lesions in the oral mucosa ( 25, 26). This underscores the potential therapeutic benefits of the J8H antibody, a reagent that inhibits α6 cleavage and not α6-dependent adhesion.
α6 integrin is used by hematopoietic stem cells to target the bone ( 46). The ability of the α6 integrin RR mutation to reduce the metastatic potential of tumor cells homing to bone occurs in the presence of endogenous WT α6 integrin. This leads to speculation that cleavage of the receptor has a dominant role in the process. The results indicate that both the time to metastasis and the number of mice developing bone lesions were substantially reduced in the PC3B1-RR group. In contrast to the antibody blocking experiments, the majority of the animals did not develop bone lesions over the 6-week course of the study. Necropsies of the animals receiving tumor cell injections did not reveal other common sites of metastasis (lung, liver, or adrenal gland), suggesting that circulating tumor cells were either eliminated from the mouse or achieved a level of dormancy ( 47, 48) in the animal. Further experiments using labeled cells and sensitive imaging technology as developed by other groups ( 49) could distinguish these possibilities.
It is also interesting to note that, after week 6, ∼40% of the animals injected with PC3B1-RR mutant cells developed a detectable metastatic lesion in bone. Although these lesions were progressive, the rate of progression compared with PC3B1-WT was slow as determined by the radiographic features of observed lesions. Termination of these animals was not required because metastases did not produce aggressive lesions leading to pathologic fractures. This suggests that tumor cells that possess uncleavable α6 integrin may eventually adapt to and colonize an osseous microenvironment to produce lytic lesions but remain less aggressive in nature. This result is consistent with the reported less aggressive phenotype of the RR mutant tumor cells directly injected into the distal end of a mouse femur ( 28).
We note that endogenous levels of α6p observed for cell lines in culture do not correlate with secreted levels of uPA and uPA activity. PC3 cells express minimal levels of α6p, whereas DU145 cells convert a majority of α6 integrin into the cleaved product ( Fig. 3A). However, PC3 cells secrete at least 2-fold more active uPA when compared with DU145 ( 50). This suggests that uPA concentration is not the limiting factor in the regulation of integrin α6 cleavage. The ability to block α6 integrin cleavage by extracellular engagement of the receptor points to the possibility that lateral membrane associations with surface-expressed proteins, such as tetraspanins ( 51, 52) and uPA receptor (uPAR; refs. 53, 54), could influence uPA-mediated integrin cleavage in a physiologically relevant manner. Current work investigating this possibility may reveal other potential cell surface targets for disruption of extravasation of prostate cancer to bone.
The amount of α6p in vitro is not prognostic for bone metastasis in vivo. However, the inability to produce α6p will significantly hinder bone metastasis development in mice. It will be important to have a method to detect cleaved α6p in vivo to determine if the cleaved integrin could serve as a prognostic factor. We are currently developing an ELISA to determine if the released extracellular fragment of α6 integrin is detectable in blood. We consider it likely that α6 cleavage may add to the multiple molecular features required to reliably detect tumor cells with metastatic potential.
Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.
Grant support: NIH grants T32CA009213, P30 CA23074, and PO1 CA56666.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
We thank the dedicated staff of the Tissue Acquisition Core Service, the Experimental Mouse Shared Service, and the Flow Cytometry Service located in The Arizona Cancer Center.
- Received February 2, 2009.
- Revision received March 23, 2009.
- Accepted April 22, 2009.
- ©2009 American Association for Cancer Research.